Moxonidine and Ramipril in Patients with Hypertension and Obstructive Pulmonary Disease
- First Online:
- 19 Downloads
Objectives: To investigate the tolerability and efficacy of moxonidine in the treatment of arterial hypertension in patients with obstructive pulmonary disease. The ACE inhibitor ramipril was used as a reference agent.
Patients and Methods: A group of 104 adult patients with arterial hypertension and respiratory disorders took part in a double-blind, randomised, parallel-group, single-centre study. During the eight-week treatment phase, patients received either moxonidine (0.2 or 0.4 mg/day) or the ACE inhibitor ramipril (2.5 or 5 mg/day).
Results: Small, nonsignificant changes in arterial oxygen partial pressure (PaO2) were observed during the treatment period with both moxonidine and ramipril. Forced expiratory volume in one second (FEV1) remained constant during treatment with moxonidine. A slight decrease in FEV1 with ramipril was not statistically significant (p > 0.1). The 24-hour blood pressure measurements showed that systolic and diastolic blood pressures were reduced with moxonidine (p = 0.018 and p = 0.009, respectively) and with ramipril (p < 0.001 for both measurements).
Conclusions: Moxonidine and ramipril exhibited comparable antihypertensive efficacy. Lung function was unchanged during treatment with moxonidine, suggesting that this new antihypertensive agent may be an appropriate choice of medication for patients with essential hypertension and concomitant obstructive pulmonary disease.
- 1.Kaplan NM. Hypertension in the population at large. In: Kaplan NM, editor. Clinical hypertension, Baltimore: Williams & Wilkens, 1994: 1–22Google Scholar
- 8.Ernsberger P. The I1-imidazoline receptor agonist moxonidine: molecular, cellular and organismic actions. Rev Contemp Pharmacother 1998; 9: 441–62Google Scholar
- 9.McNeill RS. Effects of a beta-adrenergic-blocking agent, propranolol, on asthmatics. Lancet 1984; II: 1101–2Google Scholar
- 11.Wilkens H, Wilkens JH, Hecht M, et al. Effect of moxonidine, an alpha-2-adrenergic agonist, on histamine-induced bronchial constriction and ventilatory occlusion responses to carbon dioxide in asthmatics. 3rd Cardiovascular Pharmacology International Symposium, 1989, KyotoGoogle Scholar
- 12.Jaeger B, Verboom C, Brunner H. The clinical efficacy of moxonidine in hypertension. Rev Contemp Pharmacother 1998; 9: 463–71Google Scholar
- 19.Sides GD, Leschinger MI, Walenta R, et al. The tolerability and adverse event profile of moxonidine. Rev Contemp Pharmacother 1998; 9: 491–98Google Scholar
- 20.Feuring M, Cassel W, Stawenow D, et al. Safety of moxonidine in patients with mild-to-moderate hypertension and chronic pulmonary disease [abstract]. Eur J Clin Pharmacol 1996; 50: 533Google Scholar